NCT00251797View on ClinicalTrials.gov

A Phase I Trial Using Combination Irinotecan and Thalidomide for Recurrent CNS Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 31, 2000

Primary Completion Date

June 30, 2006

Study Completion Date

June 30, 2006

Conditions
Brain and Nervous SystemCancer
Interventions
DRUG

Irinotecan

Irinotecan: 300 to 350 mg/m2 mixing with 250 cc. Dextrose injection. IV infusion over 90 minutes D1 and repeat every 21 days

DRUG

Thalidomide

Thalidomide 50 mg capsule starting from 4 tablets per day Oral D 3 to D 19 of each cycle

Trial Locations (1)

87131

University of New Mexico, Albuquerque

All Listed Sponsors
lead

University of New Mexico

OTHER

NCT00251797 - A Phase I Trial Using Combination Irinotecan and Thalidomide for Recurrent CNS Tumors | Biotech Hunter | Biotech Hunter